Generation and Characterization of Siglec-F-Specific Monoclonal Antibodies

  • Sima Shahmohammadi-Farid Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran AND Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  • Roya Ghods Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran AND Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Mahmood Jeddi-Tehrani Monoclonal Antibody Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
  • Ali-Ahmad Bayat Monoclonal Antibody Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
  • Nazanin Mojtabavi Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Alireza Razavi Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  • Amir-Hassan Zarnani Reproductive Immunology Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran AND Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Keywords: Epitopes, Flow cytometry, Monoclonal antibody, Native protein, Siglec-F, Western blotting


Siglec-F (SF) is a surface glycoprotein expressed by mouse eosinophils and induces caspase- and mitochondria-dependent apoptosis after engagement with its cognate ligand or specific antibodies. This targeting eosinophils by monoclonal antibodies may help diverse diseases associated with increased frequency of eosinophils including allergy and asthma. In this paper, production of murine and rat monoclonal antibodies (mAbs) against Siglec-F has been addressed. Balb/c mice were immunized with siglec-F1 (SF1) and siglec-F2 (SF2) synthetic peptides conjugated to a carrier protein. Rats were immunized with Chinese hamster ovary CHO cells overexpressing Siglec-F (CHO-SF) or with Siglec-F-human immunoglobulin FC fusion protein (CHO-SF-Ig). Hybridomas were produced by standard protocol and screened for their reactivity by enzyme-linked immunosorbent assay (ELISA), western blotting (WB), and flow cytometry. In parallel, polyclonal antibodies were generated in New Zealand White rabbits immunized with SF1 and SF2 peptides. Three mouse and three rat mAbs were generated against synthetic peptides and SF-Ig, respectively. All mouse monoclonal and rabbit polyclonal antibodies reacted well with immunizing molecules in ELISA and detected specific band of Siglec-F in WB. However, they failed to detect native molecule in flow cytometry analysis. Quite the contrary, rat mAbs did not reacted with the denatured protein in WB, instead exhibited significant reactivity with CHO-SF cells in flow cytometry. Based on the heavily glycosylated nature of Siglec-F, it seems that generation of anti-SF antibodies able to detect native protein needs a properly folded molecule for immunization. Monoclonal antibodies reported here are invaluable tools for studying linear and conformation epitopes of SF and tracing mouse eosinophils.


  1. Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology 2006; 16(1):1R-27R.
  2. Macauley MS, Crocker PR, Paulson JC .Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014; 14(10):653-66.
  3. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7(4):255-66.
  4. Robertson SA, Mau VJ, Hudson SN, Tremellen KP. Cytokine-leukocyte networks and the establishment of pregnancy. Am J Reprod Immunol 1997; 37(6):438-42.
  5. Daëron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224:11-43.
  6. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 2001; 97(1):288-96.
  7. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004; 173(11):6841-9.
  8. Crocker PR, Varki A. Siglecs in the immune system. Immunology 2001; 103(2):137-45.
  9. Tateno H, Crocker PR, Paulson JC. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 2005; 15(11):1125-35.
  10. Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, Soroosh P, et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009; 183(8):5333-41.
  11. Possa SS, Leick EA, Prado CM, Martins MA, Tibério IF. Eosinophilic inflammation in allergic asthma. Front Pharmacol 2013; 4:46.
  12. Farid SSh, Mirshafiey A, Razavi A. Siglec-8 and Siglec-F, the new therapeutic targets in asthma. Immunopharmacol Immunotoxicol 2012; 34(5):721-6.
  13. Bousquet j, Chiron R, et al. Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther 2008; Dec;8(12):1921-8.
  14. Ghods R, Ghahremani MH, Darzi M, Mahmoudi AR, Yeganeh O, Bayat AA, et al. Immunohistochemical characterization of novel murine monoclonal antibodies against human placenta-specific 1. Biotechnol Appl Biochem 2014; 61(3):363-9.
  15. Shojaeian S, Allameh A, Zarnani AH, Chamankhah M, Ghods R, Bayat AA, et al. Production and characterization of monoclonal antibodies against the extracellular domain of CA 125. Immunol Invest 2010; 39(2):114-31.
  16. Simon D, Wardlaw A, Rothenberg ME. Rothenberg. Organ-specific eosinophilic disorders of the skin, lung and gastrointestinal tract. J Allergy Clin Immunol 2010; 126(1):3-13.
  17. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22(6):337-42.
  18. Zhang JQ1, Biedermann B, Nitschke L, Crocker PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004; 34(4):1175-84.
  19. Pope SM, Fulkerson PC, Blanchard C, Akei HS, Nikolaidis NM, Zimmermann N, et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 2005; 280(14):13952-61.
  20. O'Reilly MK, Paulson JC. Paulson. Siglecs as targets for therapy in immune cell mediated disease. Trends Pharmacol Sci 2009; 30(5):240-8.
  21. Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, et al. Specific inactivation of two immunomodulatory SIGLEC genes during human evolution. Proc Natl Acad Sci U S A 2012; 109(25):9935-40.
  22. Cho JY, Song DJ, Pham A, Rosenthal P, Miller M, Dayan S, et al. Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13. Respir Res 2010; 11:154.
  23. Zhang M1, Angata T, Cho JY, Miller M, Broide DH, Varki A. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007; 109(10):4280-7.

How to Cite
Shahmohammadi-Farid S, Ghods R, Jeddi-Tehrani M, Bayat A-A, Mojtabavi N, Razavi A, Zarnani A-H. Generation and Characterization of Siglec-F-Specific Monoclonal Antibodies. Iran J Allergy Asthma Immunol. 16(6):460-470.
Original Article(s)